Rapamycin, a potent immunomodulatory drug, has shown promise in the amelioration of
numerous age-associated diseases including cancer, Alzheimer's disease and cardiac
hypertrophy. Yet the elderly, the population most likely to receive therapeutic rapamycin, are
already at increased risk for infectious disease; thus concern exists that rapamycin may
exacerbate age-associated immune dysfunctions and worsen infection outcomes. Herein,
we examined the impact of enteric delivered rapamycin monotherapy (eRapa) on the …